A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2012
At a glance
- Drugs Sepantronium bromide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 06 Jun 2012 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 23 Oct 2007 Status changed from in progress to completed.
- 12 Dec 2006 Status change